(NASDAQ: ALMS) Alumis's forecast annual revenue growth rate of 14.57% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Alumis's revenue in 2025 is $17,389,000.On average, 3 Wall Street analysts forecast ALMS's revenue for 2025 to be $1,435,707,901, with the lowest ALMS revenue forecast at $946,058,005, and the highest ALMS revenue forecast at $1,762,195,570. On average, 2 Wall Street analysts forecast ALMS's revenue for 2026 to be $495,634,506, with the lowest ALMS revenue forecast at $414,026,190, and the highest ALMS revenue forecast at $577,242,822.
In 2027, ALMS is forecast to generate $1,822,748,941 in revenue, with the lowest revenue forecast at $1,468,949,688 and the highest revenue forecast at $2,176,548,193.